Skip to main content
Xspray Pharma logo

Xspray Pharma — Investor Relations & Filings

Ticker · XSPRAY ISIN · SE0023312764 LEI · 549300NGRQCNZ3X4L157 ST Manufacturing
Open in API
Filings indexed 254 across all filing types
Latest filing 2024-12-04 Share Issue/Capital Cha…
Country SE Sweden
Listing ST XSPRAY

About Xspray Pharma

https://xspraypharma.com/

Xspray Pharma is a pharmaceutical company that utilizes its patented technology platform to develop improved versions of marketed drugs, primarily focusing on Protein Kinase Inhibitors (PKIs) for cancer treatment. The company's core innovation lies in its ability to create stable, amorphous (non-crystalline) formulations of active pharmaceutical ingredients. This unique approach enables the development of product candidates that can bypass the secondary patents of original crystalline drugs, facilitating market entry upon the expiration of the primary substance patent. Xspray Pharma's products are designed to offer clinical benefits for patients compared to the original branded drugs and their subsequent generic equivalents.

Recent filings

Filing Released Lang Actions
Xspray offentliggör slutligt utfall i företrädesemissionen
Share Issue/Capital Change Classification · 95% confidence The document is a press release from Xspray Pharma AB announcing the final results of a rights issue (företrädesemission). It details the subscription outcome, the amount raised, and the impact on share capital. While it discusses a capital-related event, it is a formal announcement of the results of a completed offering rather than a prospectus or a standalone financial report. According to the 'Menu vs Meal' rule, this is a corporate announcement regarding a specific event (capital change/financing outcome). Given the specific nature of the announcement regarding the final outcome of a share issuance, it fits best under 'Share Issue/Capital Change'.
2024-12-04 Swedish
Xspray publishes the final outcome of the rights issue
Share Issue/Capital Change Classification · 100% confidence The document is a press release from Xspray Pharma AB announcing the final outcome of a rights issue. It details the subscription results, the amount of capital raised, and the impact on share capital and total shares. While it discusses capital changes, it is fundamentally an announcement of the results of a corporate action (the rights issue) rather than the prospectus or the legal filing itself. According to the 'Menu vs Meal' rule, this is an announcement of a corporate event/result. Given the specific nature of the content (rights issue outcome), it fits best under 'Share Issue/Capital Change' (SHA) as it details the issuance of new shares and the resulting capital structure change.
2024-12-04 English
Strong interest in Xspray Pharma AB’s rights issue – preliminary outcome is published
Share Issue/Capital Change Classification · 99% confidence The document is a press release announcing the preliminary outcome of a 'rights issue' (a type of fundraising/capital activity). It details the subscription percentages, the expected proceeds (SEK 135 million), and the resulting increase in share capital. This content directly relates to the company's financing activities and capital structure changes. This aligns perfectly with the definition for Capital/Financing Update (CAP). Although it mentions a prospectus was published, the document itself is the announcement of the results, not the prospectus or a general regulatory filing.
2024-12-02 English
Starkt intresse för Xspray Pharma ABs företrädesemission - preliminärt utfall offentliggörs
Capital/Financing Update Classification · 98% confidence The document is a press release from Xspray Pharma AB announcing the preliminary outcome of a rights issue ('förtädesemission'). It details the subscription rate (over-subscribed at 117%), the capital raised (approx. 135 MSEK), and the resulting increase in share capital and total number of shares. It also provides timelines for final results and trading of new shares. This content directly relates to capital structure changes and fundraising activities. This aligns perfectly with the definition for 'Capital/Financing Update' (CAP). Although it is a press release, the core subject matter is the financing event itself, not just the announcement of a report (which would suggest RPA or RNS). Since the document is substantial (15,065 characters) and contains the detailed results, it is classified as the primary event document.
2024-12-02 Swedish
Xspray publishes prospectus relating to the rights issue
Report Publication Announcement Classification · 100% confidence The document is a press release announcing the publication and approval of a prospectus for a rights issue. It explicitly states that the prospectus has been made available on the company's website and other platforms. According to the 'Menu vs Meal' rule, an announcement regarding the publication of a report (in this case, a prospectus) is classified as a Report Publication Announcement (RPA).
2024-11-14 English
Xspray offentliggör prospekt avseende företrädesemissionen
Report Publication Announcement Classification · 100% confidence The document is a press release from Xspray Pharma AB announcing that a prospectus for a rights issue has been approved and registered by the Swedish Financial Supervisory Authority (Finansinspektionen). It provides links to the prospectus and details regarding the offering, but it is not the prospectus itself. According to the 'Menu vs Meal' rule, an announcement of a report or document that provides a link to the actual file is classified as a Report Publication Announcement (RPA).
2024-11-14 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.